866-997-4948(US-Canada Toll Free)

Diabetic Foot Ulcers - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 157 Pages

Diabetic Foot Ulcers - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers Pipeline Review, H2 2016, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 16, 5, 16, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Diabetic Foot Ulcers.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Foot Ulcers Overview 8
Therapeutics Development 9
Pipeline Products for Diabetic Foot Ulcers - Overview 9
Pipeline Products for Diabetic Foot Ulcers - Comparative Analysis 10
Diabetic Foot Ulcers - Therapeutics under Development by Companies 11
Diabetic Foot Ulcers - Therapeutics under Investigation by Universities/Institutes 13
Diabetic Foot Ulcers - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Diabetic Foot Ulcers - Products under Development by Companies 18
Diabetic Foot Ulcers - Products under Investigation by Universities/Institutes 21
Diabetic Foot Ulcers - Companies Involved in Therapeutics Development 22
ANP Technologies Inc 22
CardioVascular BioTherapeutics Inc 23
Celgene Corp 24
Chrysalis BioTherapeutics Inc 25
CytoTools AG 26
EyeGene Inc 27
FirstString Research Inc 28
Genentech Inc 29
GlaxoSmithKline Plc 30
Human Stem Cells Institute 31
Izun Pharmaceuticals Corp 32
Karyopharm Therapeutics Inc 33
Lakewood-Amedex Inc 34
Lytix Biopharma AS 35
Mallinckrodt Plc 36
MediWound Ltd 37
NovaLead Pharma Pvt Ltd 38
Oneness Biotech Co Ltd 39
Osiris Therapeutics Inc 40
Pherecydes Pharma SA 41
Plurogen Therapeutics Inc 42
TechnoPhage SA 43
TGV-Laboratories 44
Theravasc Inc 45
Topadur Pharma AG 46
USV Pvt Ltd 47
viDA Therapeutics Inc 48
ViroMed Co Ltd 49
Diabetic Foot Ulcers - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Target 51
Assessment by Mechanism of Action 53
Assessment by Route of Administration 55
Assessment by Molecule Type 57
Drug Profiles 59
3K3A-APC - Drug Profile 59
ALLO-ASC - Drug Profile 61
ANP-017 - Drug Profile 62
AP-102 - Drug Profile 63
APO-2 - Drug Profile 64
becaplermin biosimilar - Drug Profile 65
Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile 66
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile 68
CL-05 - Drug Profile 69
CODA-001 - Drug Profile 72
CVBT-141B - Drug Profile 74
Cyndacel-M - Drug Profile 75
daprodustat - Drug Profile 76
EG-Decorin - Drug Profile 78
epidermal growth factor biosimilar - Drug Profile 79
EscharEx - Drug Profile 80
esmolol hydrochloride - Drug Profile 82
Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 83
Granexin - Drug Profile 84
Heberprot-P - Drug Profile 86
IMSP-001 - Drug Profile 87
IZN-6D4 - Drug Profile 88
LTX-109 - Drug Profile 89
MT-003 - Drug Profile 91
Mul-1867 - Drug Profile 92
Neovasculgen - Drug Profile 93
Nu-2 - Drug Profile 94
Nu-3 - Drug Profile 95
ON-101 - Drug Profile 97
OTI-1501 - Drug Profile 99
PDA-002 - Drug Profile 100
PluroGel N - Drug Profile 101
PP-2351 - Drug Profile 102
Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 103
RG-7880 - Drug Profile 104
rusalatide acetate - Drug Profile 105
selinexor - Drug Profile 108
sodium nitrite SR - Drug Profile 127
Stathmin-1 - Drug Profile 129
TOPN-53 - Drug Profile 130
TP-102 - Drug Profile 131
V-10 - Drug Profile 132
VM-202 - Drug Profile 133
VTI-1000 Series - Drug Profile 137
VTI-3000 Series - Drug Profile 138
Diabetic Foot Ulcers - Dormant Projects 139
Diabetic Foot Ulcers - Discontinued Products 143
Diabetic Foot Ulcers - Product Development Milestones 144
Featured News & Press Releases 144
Appendix 153
Methodology 153
Coverage 153
Secondary Research 153
Primary Research 153
Expert Panel Validation 153
Contact Us 153
Disclaimer 154

List of Tables
Number of Products under Development for Diabetic Foot Ulcers, H2 2016 12
Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Number of Products under Development by Companies, H2 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Development, H2 2016 19
Comparative Analysis by Unknown Stage Development, H2 2016 20
Products under Development by Companies, H2 2016 21
Products under Development by Companies, H2 2016 (Contd..1) 22
Products under Development by Companies, H2 2016 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2016 24
Diabetic Foot Ulcers - Pipeline by ANP Technologies Inc, H2 2016 25
Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics Inc, H2 2016 26
Diabetic Foot Ulcers - Pipeline by Celgene Corp, H2 2016 27
Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, H2 2016 28
Diabetic Foot Ulcers - Pipeline by CytoTools AG, H2 2016 29
Diabetic Foot Ulcers - Pipeline by EyeGene Inc, H2 2016 30
Diabetic Foot Ulcers - Pipeline by FirstString Research Inc, H2 2016 31
Diabetic Foot Ulcers - Pipeline by Genentech Inc, H2 2016 32
Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline Plc, H2 2016 33
Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H2 2016 34
Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corp, H2 2016 35
Diabetic Foot Ulcers - Pipeline by Karyopharm Therapeutics Inc, H2 2016 36
Diabetic Foot Ulcers - Pipeline by Lakewood-Amedex Inc, H2 2016 37
Diabetic Foot Ulcers - Pipeline by Lytix Biopharma AS, H2 2016 38
Diabetic Foot Ulcers - Pipeline by Mallinckrodt Plc, H2 2016 39
Diabetic Foot Ulcers - Pipeline by MediWound Ltd, H2 2016 40
Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H2 2016 41
Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co Ltd, H2 2016 42
Diabetic Foot Ulcers - Pipeline by Osiris Therapeutics Inc, H2 2016 43
Diabetic Foot Ulcers - Pipeline by Pherecydes Pharma SA, H2 2016 44
Diabetic Foot Ulcers - Pipeline by Plurogen Therapeutics Inc, H2 2016 45
Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H2 2016 46
Diabetic Foot Ulcers - Pipeline by TGV-Laboratories, H2 2016 47
Diabetic Foot Ulcers - Pipeline by Theravasc Inc, H2 2016 48
Diabetic Foot Ulcers - Pipeline by Topadur Pharma AG, H2 2016 49
Diabetic Foot Ulcers - Pipeline by USV Pvt Ltd, H2 2016 50
Diabetic Foot Ulcers - Pipeline by viDA Therapeutics Inc, H2 2016 51
Diabetic Foot Ulcers - Pipeline by ViroMed Co Ltd, H2 2016 52
Assessment by Monotherapy Products, H2 2016 53
Number of Products by Stage and Target, H2 2016 55
Number of Products by Stage and Mechanism of Action, H2 2016 57
Number of Products by Stage and Route of Administration, H2 2016 59
Number of Products by Stage and Molecule Type, H2 2016 61
Diabetic Foot Ulcers - Dormant Projects, H2 2016 142
Diabetic Foot Ulcers - Dormant Projects (Contd..1), H2 2016 143
Diabetic Foot Ulcers - Dormant Projects (Contd..2), H2 2016 144
Diabetic Foot Ulcers - Dormant Projects (Contd..3), H2 2016 145
Diabetic Foot Ulcers - Discontinued Products, H2 2016 146

List of Figures
Number of Products under Development for Diabetic Foot Ulcers, H2 2016 12
Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Products, H2 2016 19
Assessment by Monotherapy Products, H2 2016 53
Number of Products by Top 10 Targets, H2 2016 54
Number of Products by Stage and Top 10 Targets, H2 2016 54
Number of Products by Top 10 Mechanism of Actions, H2 2016 56
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 56
Number of Products by Top 10 Routes of Administration, H2 2016 58
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 58
Number of Products by Top 10 Molecule Types, H2 2016 60
Number of Products by Stage and Top 10 Molecule Types, H2 2016 60

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *